A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation ...

Foresight’s technology will be integrated into Natera’s Signatera platform and is expected to be launched for clinical use in ...

Startup solves longstanding computer vision challenge with proprietary dataset; beta testing shows 84% of users discover previously unknown form deficiencies VANCOUVER, BC / ACCESS Newswire / December ...

At a steaming creek in California’s Lassen Volcanic National Park, a tiny amoeba just raised the heat ceiling for complex ...

This comprehensive review examines vitamin B12 absorption, physiological roles, deficiency states, and dietary sources, with ...

Worldwide Stablecoin Payment Network (WSPN), a leading provider of next-generation stablecoin infrastructure, today announced a strategic partnership with ArrivalX, a global digital payments and ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutationPhase 2 results ...

Some children have already died and only a minority who inherit the mutation will escape cancer, a new report stated on ...

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutation ...

Given the recent interest in longevity, antiaging supplements are rising in popularity, and among them, NAD+ is at the ...

Nine small health issues that could be an early sign of lung cancer - As the NHS offers a ‘revolutionary’ blood test, here ...